Palatin Technologies (PTN) FCF Margin (2010 - 2026)

Palatin Technologies' (PTN) quarterly FCF Margin came in at 113.64% in Q1 2026, up 97.26% on a QoQ basis from 4142.55% in Q4 2025.

Palatin Technologies (PTN) FCF Margin (2010 - 2026) Analysis & Trends

Palatin Technologies (PTN) has 14 years of FCF Margin data on file, last reported at 113.64% in Q1 2026.

Quarterly FCF Margin changed N/A year-over-year to 113.64% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 116.35% (up 665364.0% YoY) and the FY2024 annual result came in at 701.63%, down 8924.0% from the prior year.
FCF Margin rose to 113.64% in Q1 2026, from 4142.55% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 18.34% in Q3 2025 to a low of 4428.05% in Q1 2022.
A 5-year average of 1289.53% and a median of 751.9% in 2022 frame the typical range for FCF Margin.
Annual changes were most pronounced in 2022 — FCF Margin jumped 651202 bps — and 2024, when it tumbled 130158 bps.
Tracing PTN's FCF Margin over 5 years: stood at 954.72% in 2022, then soared by 46 bps to 516.85% in 2023, then slumped by 258 bps to 1850.68% in 2024, then sank by 124 bps to 4142.55% in 2025, then jumped by 97 bps to 113.64% in 2026.
The last three FCF Margin figures came in at 113.64% (Q1 2026), 4142.55% (Q4 2025), and 18.34% (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.82 Bn	131.97 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	13.35%
3	Argenx Se	65.27 Bn	60.09 Bn	1.37 Bn	-
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.14 Bn	9.75 Bn	668.28 Mn	41.07%
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.26 Bn	26.42 Bn	-	70.82%
10	Palatin Technologies	39.40 Mn	39.40 Mn	-	-113.64%

Download Data